Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Xiangmin Tong"'
Autor:
Jing Du, Yong-Lie Zhou, Qiangan Jing, Xueying Ren, Ying Wang, Xiangmin Tong, Huanjuan Li, Lijuan Fang, Chen Yang, Xu Wang, Chaoting Zhou, Yi Zhou, Luyang Wang, Yanchun Li, Wanye Hu
Publikováno v:
Cell Death and Disease, Vol 12, Iss 7, Pp 1-14 (2021)
Cell Death & Disease
Cell Death & Disease
Pancreatic ductal adenocarcinoma (PDAC) is an extremely lethal cancer with limited treatment options. Cisplatin (DDP) is used as a mainstay of chemotherapeutic agents in combination with other drugs or radiotherapy for PDAC therapy. However, DDP exhi
Autor:
Hongying Pan, Xiangmin Tong, Shufang Xie, Chen Yang, Weimin Fan, Shibing Wang, Wen Lei, Yi Wu
Publikováno v:
Oncology Reports
Non‑Hodgkin lymphoma (NHL) is a form of lymphoid malignancy, with diffuse large B cell lymphoma (DLBCL) being the most common NHL isoform. Approximately half of patients with DLBCL are successfully cured via first‑line Rituximab, Cyclophosphamide
Autor:
Yongjian Chen, Yuzhou Chen, Yanping Zhou, FeiFei Zho, Sumei Wang, Sujie Zheng, Yuhuan Shen, Xiangmin Tong, Jing Du, Yanchun Li
Publikováno v:
Clinica chimica acta; international journal of clinical chemistry. 532
IgE multiple myeloma (MM) is a rare subtype of MM that is easily misdiagnosed. We report a rare case of IgE-MM and investigate the application of the SLiM-CRAB criteria to screen for high-risk smoldering MM (SMM) patients, so as to summarize the caus
Autor:
Shida, Chen, Mingqi, Zhou, Jing, Yang, Yong-Ran, Cheng, Yanchun, Li, Kang, Lu, Wanye, Hu, Nanni, Hua, Ying, Wang, Xiangmin, Tong
Publikováno v:
Clinical Laboratory. 68
The goal of this study is to explore the clinical value of routine tests in multiple myeloma (MM).A total of 179 MM patients, newly diagnosed in our hospital from January 2010 to December 2018 (case group), as well as 352 cases of healthy individuals
Autor:
Nanni Hua, Anxian Chen, Chen Yang, Hui Dong, Xianglei He, Guoqing Ru, Xiangmin Tong, Feifei Zhou, Shibing Wang
Background Fibrinogen-like-protein 1 (FGL1), a member of the fibrinogen-related protein (FREP) family, is a major ligand of the immune inhibitory receptor lymphocyte-activation gene 3 (LAG-3). While FGL1 is strongly implicated in the development and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f604d331dd5c407860b713a8ab91fe1
https://doi.org/10.21203/rs.3.rs-1037866/v2
https://doi.org/10.21203/rs.3.rs-1037866/v2
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 13, Iss 1, Pp 1-11 (2021)
Cell Death and Disease, Vol 13, Iss 1, Pp 1-11 (2021)
Acute myeloid leukemia (AML) is an aggressive and heterogeneous clonal hematologic malignancy for which novel therapeutic targets and strategies are required. Emerging evidence suggests that WTIP is a candidate tumor suppressor. However, the molecula
Autor:
Qiliang Lu, Yang Liu, Zhi Zeng, Lifen Zhu, Linjun Hu, Xin Liu, Qiuran Xu, Junjun Zhao, Xiangmin Tong
Publikováno v:
International Journal of Medical Sciences
Diffuse large B-cell lymphoma (DLBCL) is commonly treated with R-CHOP, but ~30 to 50% of the patients are poorly responsive to this strategy. Geniposide, an extract from the Gardenia jasminoides Ellis, plays antitumor roles in human gastric cancer, h
Autor:
Jiahui Wang, Yang Guo, Zunqiang Xiao, Xiangmin Tong, Yazhao Li, Qiuran Xu, Linjun Hu, Xin Liu, Qiaojuan Zhu
Publikováno v:
Journal of Cellular and Molecular Medicine
The aberrant expression and dysfunction of long non‐coding RNAs (lncRNAs) have been identified as critical factors governing the initiation and progression of different human cancers, including diffuse large B‐cell lymphoma (DLBCL). LncRNA small
Autor:
Jia-Yu Hu, Chaoting Zhou, Jing Yang, Haifeng Xu, Qiangan Jing, Hairui Wang, Yanchun Li, Wanye Hu, Luyang Wang, Xu Wang, Chen Yang, Huanjuan Li, Xiangmin Tong, Ying Wang, Yi Zhou, Jing Du, Xueying Ren
Publikováno v:
Redox Biology
Redox Biology, Vol 46, Iss, Pp 102122-(2021)
Redox Biology, Vol 46, Iss, Pp 102122-(2021)
Hepatocellular carcinoma (HCC) is one of the paramount causes of cancer-related death worldwide. Despite recent advances have been made in clinical treatments of HCC, the general prognosis of patients remains poor. Therefore, it is imperative to deve
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 139, Iss, Pp 111573-(2021)
The incidence of hematological malignancies such as multiple myeloma, leukemia, and lymphoma has increased over time. Although bone marrow transplantation, immunotherapy and chemotherapy have led to significant improvements in efficacy, poor prognosi